Double-dosing GLP-1 agonists can lead to severe side effects, including dangerously low blood sugar, which could be life-threatening if not treated
They say, well, it's not FDA approved
The GLP-1R is expressed in many tissues, including pancreatic islets, the central nervous system, lung, kidney, heart, intestine, and also on immune cells ( When secreted by L cells, GLP-1 either functions in an endocrine manner, being released into the blood stream where it is rapidly inactivated by DPP-4 with a half-life of about 2 min, or exerts paracrine effects like stimulating neurons
In 2022, citing shortages of the drugs, the FDA allowed compounding pharmacies to make them but with the shortages over, the FDA stopped allowing compounding pharmacies to make tirzepatide (Mounjaro and Zepbound) in March, and semaglutide (Ozempic and Wegovy) last week
D., Rao, M., Gilbertson, D
UK Dispatch Orders confirmed before the daily cut-off ship the same working day from our UK facility, with tracked next-working-day UK delivery as standard